Actively Recruiting
Intervention to Improve Communication and Medication Adherence in Lupus
Led by Duke University · Updated on 2025-09-30
480
Participants Needed
1
Research Sites
230 weeks
Total Duration
On this page
Sponsors
D
Duke University
Lead Sponsor
N
National Institute on Minority Health and Health Disparities (NIMHD)
Collaborating Sponsor
AI-Summary
What this Trial Is About
CO-LEAD is an intervention to improve patient-provider communication and medication adherence among patients with systemic lupus erythematosus (SLE). The purpose of this study is to optimize the culturally appropriate delivery and test the effect of the CO-LEAD intervention, which includes the following: 1. clinicians will be provided with a program to teach them to use effective communication strategies with patients to review real-time pharmacy refill date, engage and formulate solutions to adherence barriers, and collaboratively overcome adherence barriers. 2. use of a reliable and valid patient-reported measure of the extent of and reasons for nonadherence that helps patients identify and communicate their adherence barriers with clinicians proactively, efficiently, and comprehensively.
CONDITIONS
Official Title
Intervention to Improve Communication and Medication Adherence in Lupus
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- English-speaking and able to provide consent
- Diagnosed with systemic lupus erythematosus (SLE) and receiving care from enrolled clinicians
- Prescribed at least one SLE medication and filling medications at a pharmacy linked to Surescripts visible in Epic EMR
You will not qualify if you...
- Non-English speakers
- Patients prescribed only corticosteroids for SLE
- Patients accompanied by a third party who is unwilling or unable to remain in the waiting room during the patient's visit and who either does not wish to be audio recorded, is a minor without a parental or legal guardian, or is unable to give consent
- Clinicians involved in the investigators' pilot work at Duke University
- Clinicians expected to leave their institution within 12 months after enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Duke University
Durham, North Carolina, United States, 27710
Actively Recruiting
Research Team
K
Kai Sun, MD
CONTACT
K
Kathyrn Pollak, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here